{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:18:06Z","timestamp":1780582686581,"version":"3.54.1"},"reference-count":122,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.582025","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T07:33:28Z","timestamp":1601969608000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial Therapies, Supportive Care, and Probable Vaccines"],"prefix":"10.3389","volume":"11","author":[{"given":"Rajnish","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janmejai Kumar","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachana","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Haris","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha A.","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawaher A.","family":"Abdulhakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May N.","family":"Bin-Jumah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Alkahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed M.","family":"Abdel-Daim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Sahab","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.coviro.2014.06.002","article-title":"Antiviral drugs specific for coronaviruses in preclinical development","volume":"8","author":"Adedeji","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"key":"B3","unstructured":"SARS CoV-2 guidance document2020"},{"key":"B4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1186\/s40064-015-1490-9","article-title":"Feasibility, safety, clinical, and laboratory effects of convalescent plasma\u00a0therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol","volume":"4","author":"Arabi","year":"2015","journal-title":"Springerplus"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1093\/cid\/ciz544","article-title":"Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study","volume":"70","author":"Arabi","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12016-010-8243-x","article-title":"Hydroxychloroquine: from malaria to autoimmunity","volume":"42","author":"Ben-Zvi","year":"2012","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"8801","DOI":"10.1128\/jvi.77.16.8801-8811.2003","article-title":"The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex","volume":"77","author":"Bosch","year":"2003","journal-title":"J. Virol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2019.104541","article-title":"Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase","volume":"169","author":"Brown","year":"2019","journal-title":"Antiviral Res."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study","author":"Cai","year":"2020","journal-title":"Eng. (Beijing China)."},{"key":"B10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.antiviral.2012.06.008","article-title":"Nuclear trafficking of proteins from RNA viruses: potential target for antivirals","volume":"95","author":"Caly","year":"2012","journal-title":"Antiviral Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"104787s","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1208\/s12248-007-9000-9","article-title":"The pharmacokinetics and interactions of ivermectin in humans\u2014a mini-review","volume":"10","author":"Canga","year":"2008","journal-title":"AAPS J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jinf.2020.04.017","article-title":"Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact","volume":"81","author":"Cantini","year":"2020","journal-title":"J. Infect."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","author":"Cao","year":"2020","journal-title":"N Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"30129","DOI":"10.1016\/j.biochi.2020.05.013","article-title":"The endosomal lipid bis(monoacylglycero) phosphate as a potential key player in the mechanism of action of chloroquine against SARS-COV-2 and other enveloped viruses hijacking the endocytic pathway","author":"Carri\u00e8re","year":"2020","journal-title":"Biochimie."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019014","article-title":"Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19","author":"Cavalcanti","year":"2020","journal-title":"N Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Chaolin","year":"2020","journal-title":"Lancet."},{"key":"B18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jcv.2004.03.003","article-title":"In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds","volume":"31","author":"Chen","year":"2004","journal-title":"J. Clin. Virol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3785\/j.issn.1008-9292.2020.03.03","article-title":"A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (covid-19)","volume":"49","author":"Chen","year":"2020","journal-title":"Zhejiang Univ. (Med Sci)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.22.20040758","article-title":"). Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial","author":"Chen","year":"2020","journal-title":"medrxiv."},{"key":"B23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur. J. Clin. Microbiol Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1586\/14787210.3.2.251","article-title":"Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome","volume":"3","author":"Chihrin","year":"2005","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1021\/jm0601856","article-title":"Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities","volume":"49","author":"Christophe","year":"2006","journal-title":"J. Med. Chem."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105932","article-title":"Chloroquine and hydroxychloroquine as available weapons to fight COVID-19","volume":"55","author":"Colson","year":"2020","journal-title":"Int. J. Antimicrob Agents."},{"key":"B27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jcrc.2020.03.005","article-title":"A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19","volume":"57","author":"Cortegiani","year":"2020","journal-title":"J. Crit. Care"},{"key":"B28","unstructured":"2020"},{"key":"B29","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","volume":"117","author":"de Wit","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B30","unstructured":"DoD COVID-19 practice management guide: clinical management of COVID-192020"},{"key":"B31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discovery Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S1473-3099(20)30262-0","article-title":"Baricitinib for COVID-19: a suitable treatment","volume":"20","author":"Favalli","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/vaccines4030023","article-title":"Viral inhibition of the IFN-induced JAK\/STAT signalling pathway: development of live attenuated vaccines by mutation of viral-encoded IFN-antagonists","volume":"4","author":"Fleming","year":"2016","journal-title":"Vaccines (Basel)."},{"key":"B35","unstructured":"2020"},{"key":"B36","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/s0049-0172(10)80012-5","article-title":"Mechanism of action of hydroxychloroquine as an antirheumatic drug","volume":"23","author":"Fox","year":"1993","journal-title":"Semin. Arthritis Rheumatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1177\/0961203396005001031","article-title":"Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development","volume":"5","author":"Fox","year":"1996","journal-title":"Lupus."},{"key":"B38","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1128\/aac.46.4.977-981.2002","article-title":"In vitro and in vivo activities of anti-influenza virus compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrob Agents Chemother."},{"key":"B39","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antiviral Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1093\/cid\/ciz100","article-title":"Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness","volume":"69","author":"Gamino-Arroyo","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob Agents."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N Engl. J. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"4773","DOI":"10.1074\/jbc.AC120.013056","article-title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep23138","article-title":"Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import","volume":"6","author":"G\u00f6tz","year":"2016","journal-title":"Sci. Rep."},{"key":"B46","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/rmv.483","article-title":"Mechanisms of action of ribavirin against distinct viruses","volume":"16","author":"Graci","year":"2006","journal-title":"Rev. Med. Virol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe COVID-19","volume":"82","author":"Grein","year":"2020","journal-title":"New Engl. J. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1177\/1060028015597449","article-title":"Oral Ribavirin for the Treatment of Noninfluenza Respiratory Viral Infections: A Systematic Review","volume":"49","author":"Gross","year":"2015","journal-title":"Ann. Pharmacother."},{"key":"B49","doi-asserted-by":"publisher","first-page":"6230","DOI":"10.1093\/emboj\/17.21.6230","article-title":"CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation","volume":"17","author":"Hacker","year":"1998","journal-title":"EMBO J."},{"key":"B50","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J. Pathol."},{"key":"B51","first-page":"890","article-title":"A study of pulmonary inflammatory reaction induced by N-protein of SARS-CoV in rat models and effects of glucocorticoids on it","volume":"44","author":"Hao","year":"2005","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B52","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/d41587-020-00003-1","article-title":"Coronavirus puts drug repurposing on the fast track","volume":"38","author":"Harrison","year":"2020","journal-title":"Nat. Biotech."},{"key":"B53","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41429-020-0336-z","article-title":"Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen","volume":"73","author":"Heidary","year":"2020","journal-title":"J. Antibiot (Tokyo)."},{"key":"B54","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet."},{"key":"B55","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1378\/chest.12-2907","article-title":"Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection","volume":"144","author":"Hung","year":"2013","journal-title":"Chest."},{"key":"B56","first-page":"1","article-title":"Acute Care ISMP Medication Safety Alert","volume":"25","year":"2020","journal-title":"Special edition COVID-19."},{"key":"B57","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ceb.2019.01.001","article-title":"Inhibitors of nuclear transport","volume":"58","author":"Jans","year":"2019","journal-title":"Curr. Opin. Cell Biol."},{"key":"B58","unstructured":""},{"key":"B59","doi-asserted-by":"publisher","first-page":"14614","DOI":"10.1128\/JVI.79.23.14614-14621.2005","article-title":"ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia","volume":"79","author":"Jia","year":"2005","journal-title":"J. Virol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13075-018-1634-8","article-title":"Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines","volume":"20","author":"Jorge","year":"2018","journal-title":"Arthritis. Res. Ther."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00616","article-title":"nCOVID-19 Pandemic: From Molecular Pathogenesis to Potential Investigational Therapeutics","volume":"8","author":"Kabir","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105933","article-title":"Arguments in favor of remdesivir for treating SARS-CoV-2 infections","volume":"55","author":"Ko","year":"2020","journal-title":"Int. J. Antimicrob Agents."},{"key":"B63","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s10096-005-0004-z","article-title":"Treatment of severe acute respiratory syndrome","volume":"24","author":"Lai","year":"2005","journal-title":"Eur. J. Clin. Microbiol Infect. Dis."},{"key":"B64","first-page":"121","article-title":"Severe acute respiratory syndrome: clinical and laboratory manifestations","volume":"25","author":"Lam","year":"2004","journal-title":"Clin. Biochem. Rev."},{"key":"B65","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"B66","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/cid\/ciaa242","article-title":"Analysis of epidemiological and clinical features in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan","volume":"71","author":"Lian","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B67","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/MEJ.0b013e3280adcb56","article-title":"Hydroxychloroquine overdose: case report and recommendations for management","volume":"15","author":"Ling Ngan Wong","year":"2008","journal-title":"Eur. J. Emerg Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jgg.2020.02.001","article-title":"Potential inhibitors for 2019-nCoV coronavirus M protease from clinically proven medicines","volume":"47","author":"Liu","year":"2020","journal-title":"J. Genet. Genomics"},{"key":"B69","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1080\/22221751.2020.1745095","article-title":"Laboratory diagnosis of emerging human coronavirus infections \u2013 the state of the art","volume":"9","author":"Loeffelholz","year":"2020","journal-title":"Emerg. Microbes. Infect."},{"key":"B70","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1001\/jama.290.24.3222","article-title":"Interferon Alfacon-1 Plus Corticosteroids in Severe Acute Respiratory Syndrome: A Preliminary Study","volume":"290","author":"Loutfy","year":"2003","journal-title":"J. Am. Med. Assoc."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1126\/science.aaf1279","article-title":"Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo","volume":"352","author":"Lu","year":"2016","journal-title":"Science."},{"key":"B72","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.antiviral.2013.10.004","article-title":"Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication","volume":"100","author":"Lundberg","year":"2013","journal-title":"Antiviral Res."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID-19: A single center experience","author":"Luo","year":"2020","journal-title":"J. Med. Virol."},{"key":"B74","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.4049\/jimmunol.160.3.1122","article-title":"Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds","volume":"160","author":"Macfarlane","year":"1998","journal-title":"J. Immunol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ophtha.2010.11.017","article-title":"Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy","volume":"118","author":"Marmor","year":"2011","journal-title":"Ophthalmology."},{"key":"B76","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0002-9343(83)91265-2","article-title":"Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate","volume":"75","author":"McChesney","year":"1983","journal-title":"Am. J. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/irv.12047","article-title":"Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance","volume":"7","author":"McKimm-Breschkin","year":"2012","journal-title":"Influenza Other Respir. Vir."},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-4-6","article-title":"Pharmacologicaltreatment of COVID-19: lights and shadows","volume":"9","author":"Menzella","year":"2020","journal-title":"Drugs Context"},{"key":"B79","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1093\/jac\/dkw338","article-title":"A review of treatment modalities for Middle East Respiratory Syndrome","volume":"71","author":"Mo","year":"2016","journal-title":"J. Antimicrob Chemother."},{"key":"B80","doi-asserted-by":"publisher","first-page":"30085","DOI":"10.1016\/j.medmal.2020.03.006","article-title":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection","author":"Molina","year":"2020","journal-title":"Med. Mal Infect."},{"key":"B81","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40264-020-00966-9","article-title":"Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment","volume":"43","author":"Osborne","year":"2020","journal-title":"Drug Saf."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report","author":"Horby","year":"2020","journal-title":"N Engl. J. Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1473-3099(20)30270-X","article-title":"Baricitinib for COVID-19: a suitable treatment","volume":"20","author":"Richardson","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1001\/jama.2020.8630","article-title":"Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State","volume":"323","author":"Rosenberg","year":"2020","journal-title":"JAMA"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105945","article-title":"Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine","volume":"55","author":"Sahraei","year":"2020","journal-title":"Int. J. Antimicrob Agents."},{"key":"B86","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1473-3099(06)70361-9","article-title":"New insights into the antiviral effects of chloroquine","volume":"6","author":"Savarino","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0312-7","article-title":"COVID-19: risk for cytokine targeting in chronic inflammatory diseases","author":"Schett","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"B90","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1473-3099(20)30086-4","article-title":"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study","volume":"20","author":"Shi","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"B92","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/j.1469-0691.2004.00956.x","article-title":"Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients","volume":"10","author":"Soo","year":"2004","journal-title":"Clin. Microbiol Infect."},{"key":"B93","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"18","author":"Tang","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"B95","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.antiviral.2013.06.002","article-title":"Nuclear localization of dengue virus (DENV) 1\u20134 non-structural protein 5, protection against all 4 DENV serotypes by the inhibitor Ivermectin","volume":"99","author":"Tay","year":"2013","journal-title":"Antiviral Res."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/jth.14810","article-title":"ISTH interim guidance on recognition and management of coagulopathy in COVID-19","volume":"18","author":"Thachil","year":"2020","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa879","article-title":"Use of Baricitinib in Patients with Moderate and Severe COVID-19","author":"Titanji","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B98","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"22","author":"Vincent","year":"2005","journal-title":"Virol J."},{"key":"B99","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/1087057110390360","article-title":"An AlphaScreen\u00ae-based assay for high-throughput screening for specific inhibitors of nuclear import","volume":"16","author":"Wagstaff","year":"2011","journal-title":"J. Biomol Screen."},{"key":"B100","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1042\/BJ20120150","article-title":"Ivermectin is a specific inhibitor of importin \u03b1\/\u03b2-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus","volume":"443","author":"Wagstaff","year":"2012","journal-title":"Biochem. J."},{"key":"B101","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus, (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"B102","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"B103","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1365-2249.2004.02415.x","article-title":"Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome","volume":"136","author":"Wong","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"B104","unstructured":"Clinical management of severe acute respiratory infection when COVID-19 is suspected2020"},{"key":"B105","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with corona virus disease 2019 pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effect treatment of severe COVID-19 patients with Tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B108","doi-asserted-by":"publisher","first-page":"33","DOI":"10.14740\/jem645","article-title":"Favipiravir: A Possible Pharmaceutical Treatment for COVID-19","volume":"10","author":"Yanai","year":"2020","journal-title":"J. Endocrinol. Metab."},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104760","article-title":"The broad spectrum antiviral ivermectin targets the host nuclear transport importin \u03b1\/\u03b21 heterodimer","volume":"177","author":"Yang","year":"2020","journal-title":"Antiviral Res."},{"key":"B110","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/jmv.25729","article-title":"A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treat-ment option","volume":"92","author":"Yao","year":"2020","journal-title":"J. Med. Virol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25882","article-title":"Treatment with convalescent plasma for COVID-19 patients in Wuhan, China","author":"Ye","year":"2020","journal-title":"J. Med. Virol."},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.27.20073379","article-title":"Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19","author":"Yu","year":"2020","journal-title":"medrxiv."},{"key":"B114","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1128\/JVI.02190-07","article-title":"Cytokine responses in porcine respiratory coronavirus-infected pigs treated with corticosteroids as a model for severe acute respiratory syndrome","volume":"82","author":"Zhang","year":"2008","journal-title":"J. Virol."},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality","author":"Zhang","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B116","doi-asserted-by":"publisher","first-page":"12","DOI":"10.18632\/aging.103102","article-title":"Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19","volume":"22","author":"Zhang","year":"2020","journal-title":"Aging (Albany NY)."},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108393","article-title":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China","volume":"214","author":"Zhang","year":"2020","journal-title":"Clin. Immunol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1099\/jmm.0.05320-0","article-title":"Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China","volume":"52","author":"Zhao","year":"2003","journal-title":"J. Med. Microbiol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet."},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000000791","article-title":"Effectiveness of glucocorticoid therapy in patients with severe novel corona virus pneumonia: protocol of a randomized controlled trial","author":"Zhou","year":"2020","journal-title":"Chin Med. J. (Engl)."},{"key":"B121","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B122","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s11684-020-0754-0","article-title":"Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection","volume":"14","author":"Zou","year":"2020","journal-title":"Front. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.582025\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T03:21:55Z","timestamp":1696821715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.582025\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":122,"alternative-id":["10.3389\/fphar.2020.582025"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.582025","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"article-number":"582025"}}